High Dosages of Lipitor May Increase Diabetes Risk, Italian Study Suggests

Published on July 24, 2014 by Sandy Liebhard

Text-Size:A A A+


A new study finds that patients taking higher dosages of a statin may be more likely to develop Type 2 diabetes, a risk alleged in hundreds of Lipitor lawsuit claims.

According to a HealthDay News report on July 14th, researchers from Italy recently found that people taking more of a statin therapy may be more likely to develop the disease, compared to those taking lower amounts. The study was led by Giovanni Corrao, PhD, from the University of Milano-Bicocca, and involved data from 115,709 participants in the Italian Lombardy region.  People examined in the study began taking statins between 2003 and 2004, and continued taking them until 2010. At this time, researchers followed up with patients, and determined which ones were hospitalized for a main Type 2 diabetes diagnoses, and those who began taking an anti-diabetic agent over the 5-6 year period.

Out of more than 115,000 people, researchers found that 11,154 were diagnosed with Type 2 diabetes following use of a statin.

“Benefits of statins in reducing cardiovascular events clearly overwhelm the diabetes risk,” authors concluded. According to HealthDay, one author of the study was revealed to have ties to a pharmaceutical company.

Lipitor Lawsuits Continue to Be Filed in South Carolina Federal Court

But what about the hundreds of lawsuits alleging Lipitor diabetes complications now filed over the widely-used treatment for patients with high cholesterol? In a federal multidistrict litigation established in the U.S. District Court, District of South Carolina, court documents indicate that nearly 1,000 lawsuits have been filed by patients alleging new-onset Type 2 diabetes. Court documents indicate that 959 claims against Pfizer Inc. were included in the proceeding as of July 15th.

Claims in this Lipitor litigation similarly accuse Lipitor’s manufacturer of failing to adequately warn about side effects that may stem from use of the statin, which they claim to have been designed defectively. According to cases, Lipitor warnings adjusted after a U.S. Food and Drug Administration (FDA) mandate in February 2012 remain inefficient in warning users about the risk for Type 2 diabetes. The FDA order to statin manufacturers was issued a month after a study published in JAMA: Internal Medicine revealed that women taking drugs similar to Lipitor may be at an increased risk for the disease.

Individuals who were allegedly injured by Lipitor may be eligible to file a claim against Pfizer, Inc. Call our Firm for more information: .